What is the 13F Pro Quality Score for CTMX?

13F Pro ranks CytomX Therapeutics, Inc. (CTMX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CTMX's current score at https://13fpro.ai/company/CTMX (free sign-up required for the full ranking).

Which hedge funds own the most CTMX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CTMX include FMR, Kynam Capital Management,, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/CTMX as soon as new 13F filings post.

Where does 13F Pro source CTMX data?

All CytomX Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. CytomX Therapeutics, Inc. files with the SEC under CIK 1501989. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CTMX in?

CytomX Therapeutics, Inc. (CTMX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CTMX research updated on 13F Pro?

CTMX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CytomX Therapeutics, Inc.(CTMX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1501989 CTMX stock profile & AI dashboard →

13F Pro Quality Score

8.7/100

Rank #2,927 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

0.3/100

Profitability

3.4/100

Balance Sheet

8.2/100

Earnings Quality

9.2/100

Free Cash Flow

2.9/100

Institutional Flow

86.0/100

Revenue Scale

3.4/100

Dilution Risk

18.4/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why CTMX Scores 9/100

exact factor attribution · 2026-09-11

CTMX's composite is driven by institutional flow, held back by revenue growth and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

+1.8 pts

86th pct

Shareholder dilution

-1.6 pts

18th pct

Earnings growth

-2.3 pts

4th pct

Earnings quality

-4.1 pts

9th pct

Capital efficiency

-4.2 pts

8th pct

Profitability

-7.0 pts

3th pct

Scale

-7.0 pts

3th pct

Free cash flow

-7.1 pts

3th pct

Revenue growth

-9.9 pts

0th pct

Latest change (2026-08-06): 19 → 14 · ↓ Profit margin 19→8; ↓ Revenue scale 16→5

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

CTMX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for CytomX Therapeutics, Inc. (CTMX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CTMX at 8.7/100 on a 32-signal composite quality model, placing it at rank #2,927 of 2,962 stocks — the bottom half of the AI-ranked universe. CTMX scores in the top quartile across institutional flow (86.0). Areas of concern include revenue growth (0.3) and free cash flow (2.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 18.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), CytomX Therapeutics, Inc. reports quarterly revenue of $1.4M, net income of $-20.7M, free cash flow of $-18.1M. Top institutional holders of CTMX by reported 13-F value include FMR, Kynam Capital Management, BlackRock, based on the most recent SEC filings. CTMX trades on the Nasdaq exchange and files with the SEC under CIK 1501989. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CTMX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CytomX Therapeutics, Inc. directly from SEC EDGAR. CytomX Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 6 and 61 since 2021, currently 8.7 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about CytomX Therapeutics, Inc.

Quirks, history, and lore behind CTMX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in South San Francisco, the heart of biotech country.
2
The Numbers
With no approved products and a market cap well under $500 million, its revenue comes almost entirely from research collaborations — not sales.
3
The History
Founded in the mid-2010s, it was spun out of early-stage oncology research and quickly partnered with some of the biggest names in cancer drug development.
4
The Secret
Its core idea: build antibodies that stay switched off in healthy tissue but automatically activate inside tumors, shrinking side effects that plague conventional cancer drugs.
5
The Lore
The technology is called a Probody — a masked antibody that only unmasks in the tumor microenvironment, and it's the kind of concept that makes oncologists and investors alike sit up straight.
6
The Giveaway
Its ticker is a near-anagram of its mission: smarter cancer therapeutics built on a proprietary CX platform of conditionally activated biologics.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$1.4M

Net Income

Q2 2026

$-20.7M

Free Cash Flow

Q2 2026

$-18.1M

ROIC

Q2 2026

-31.5%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-44.8% YoY

$76.2MFY 2025

FY22 $53.2MFY23 $101.2MFY24 $138.1MFY25 $76.2M

Net Income

-154.5% YoY

$-17.4MFY 2025

FY22 $-99.3MFY23 $-569.0KFY24 $31.9MFY25 $-17.4M

Operating Income

-189.5% YoY

$-22.4MFY 2025

FY22 $-101.3MFY23 $-6.5MFY24 $25.0MFY25 $-22.4M

Total Assets

+25.7% YoY

$151.6MFY 2025

FY22 $260.9MFY23 $201.8MFY24 $120.5MFY25 $151.6M

Op. Cash Flow

+12.3% YoY

$-75.6MFY 2025

FY22 $-110.8MFY23 $-56.0MFY24 $-86.2MFY25 $-75.6M

Free Cash Flow

+12.4% YoY

$-75.8MFY 2025

FY22 $-112.5MFY23 $-56.9MFY24 $-86.5MFY25 $-75.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$76.2M -44.8%	$138.1M +36.4%	$101.2M +90.4%	$53.2M +42.5%	$37.3M -45.5%	$68.4M
Net Income	$-17.4M -154.5%	$31.9M +5700.9%	$-569.0K +99.4%	$-99.3M +14.3%	$-115.9M -78.8%	$-64.8M
Operating Income	$-22.4M -189.5%	$25.0M +485.5%	$-6.5M +93.6%	$-101.3M +12.7%	$-116.0M -44.1%	$-80.5M
Total Assets	$151.6M +25.7%	$120.5M -40.3%	$201.8M -22.7%	$260.9M -23.1%	$339.4M -5.4%	$358.7M
Operating Cash Flow	$-75.6M +12.3%	$-86.2M -53.9%	$-56.0M +49.4%	$-110.8M +6.9%	$-119.0M -2363.4%	$5.3M
Free Cash Flow	$-75.8M +12.4%	$-86.5M -52.2%	$-56.9M +49.5%	$-112.5M +6.7%	$-120.6M -4189.5%	$3.0M

Get alerted when CTMX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CytomX Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CTMX

FMR LLC
$122.7M32,714,937 sh
Kynam Capital Management, LP
$81.4M21,703,093 sh
BlackRock, Inc.
$65.8M17,559,822 sh
BANK OF AMERICA CORP /DE/
$56.6M15,082,617 sh
STATE STREET CORP
$44.1M11,747,236 sh
PERCEPTIVE ADVISORS LLC
$39.1M10,439,185 sh
VANGUARD CAPITAL MANAGEMENT LLC
$32.0M8,525,457 sh
Point72 Asset Management, L.P.
$29.3M7,811,033 sh
WELLINGTON MANAGEMENT GROUP LLP
$19.4M5,168,961 sh
VR Adviser, LLC
$18.7M4,982,124 sh

Fund	Value	Shares
FMR LLC	$122.7M	32,714,937
Kynam Capital Management, LP	$81.4M	21,703,093
BlackRock, Inc.	$65.8M	17,559,822
BANK OF AMERICA CORP /DE/	$56.6M	15,082,617
STATE STREET CORP	$44.1M	11,747,236
PERCEPTIVE ADVISORS LLC	$39.1M	10,439,185
VANGUARD CAPITAL MANAGEMENT LLC	$32.0M	8,525,457
Point72 Asset Management, L.P.	$29.3M	7,811,033
WELLINGTON MANAGEMENT GROUP LLP	$19.4M	5,168,961
VR Adviser, LLC	$18.7M	4,982,124

Companies Similar to CTMX

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

STRO

SUTRO BIOPHARMA, INC.

AI score

Very similar · 7 shared holders

PERCEPTIVE ADVISORS LLC Kynam Capital Management, LP ADAR1 Capital Management, LLC

RLAY

Relay Therapeutics, Inc.

AI score

Very similar · 19 shared holders

Kynam Capital Management, LP PERCEPTIVE ADVISORS LLC BAKER BROS. ADVISORS LP

CLDX

Celldex Therapeutics, Inc.

AI score

Very similar · 16 shared holders

Kynam Capital Management, LP BAKER BROS. ADVISORS LP Elmind Capital, LP

ZYME

Zymeworks Inc.

AI score

Very similar · 11 shared holders

PERCEPTIVE ADVISORS LLC Nextech Invest, Ltd.TEMA ETFS LLC

NRIX

Nurix Therapeutics, Inc.

AI score

Very similar · 15 shared holders

PERCEPTIVE ADVISORS LLC Kynam Capital Management, LP BAKER BROS. ADVISORS LP

GLUE

Monte Rosa Therapeutics, Inc.

AI score

Very similar · 11 shared holders

BAKER BROS. ADVISORS LP Nextech Invest, Ltd.ADAR1 Capital Management, LLC

ALMS

ALUMIS INC.

AI score

Very similar · 11 shared holders

BAKER BROS. ADVISORS LP Nextech Invest, Ltd.Elmind Capital, LP

NKTR

NEKTAR THERAPEUTICS

AI score

Similar quality profile · 13 shared holders

ADAR1 Capital Management, LLC GILDER GAGNON HOWE & CO LLC DAFNA Capital Management LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CTMX on your watchlist

Track score changes the day CytomX Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CTMX a good stock to buy?

13F Pro's AI-powered analysis of CytomX Therapeutics, Inc. (CTMX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CTMX are available on the CTMX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CTMX is classified as a small company.

Which hedge funds own CTMX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CTMX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CytomX Therapeutics, Inc.'s investment landscape.